Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma | Future Oncology
Carfilzomib: new standard of care for myeloma | PPT
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials - Mateos - 2018 -
Second Phase 3 Study Shows KYPROLIS Regimen Improves Overall Survival in Patients with Relapsed MM | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Carfilzomib - Wikipedia
PDF) Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials
PDF) The role of carfilzomib in relapsed/refractory multiple myeloma
4142-Multiple myeloma KRd (carfilzomib lenalidomide dexamethasone) | eviQ
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial - The Lancet Oncology
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database - McCurdy - 2022 - eJHaem - Wiley Online Library
Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines | Journal of Pharmacology and Experimental Therapeutics
PDF) Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: Secondary analysis from the phase 3 ASPIRE study
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment | Blood Cancer Journal
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Aumento della sopravvivenza con carfilzomib per il mieloma multiplo • NCF
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Carfilzomib: new standard of care for myeloma | PPT
KRd Efficacy | KYPROLIS® (carfilzomib)
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Mieloma multiplo: arriva in Italia carfilzomib – HarDoctor News, il Blog di Carlo Cottone
